FLUDEOXYGLUCOSE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C6H11FO5
Molecular Weight	182.1469
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O

InChI

InChIKey=AOYNUTHNTBLRMT-SLPGGIOYSA-N

InChI=1S/C6H11FO5/c7-3(1-8)5(11)6(12)4(10)2-9/h1,3-6,9-12H,2H2/t3-,4+,5+,6+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C6H11FO5
Molecular Weight	182.1469
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21614337 | https://www.ncbi.nlm.nih.gov/mesh/68019788

FLUDEOXYGLUCOSE is a fluorinated glucose analog. Its 18F radiolabelled form is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.

CNS Activity

Approval Year

PubMed

Title	Date	PubMed
Inhibition of glycosyl-phosphatidylinositol biosynthesis in Plasmodium falciparum by C-2 substituted mannose analogues.	2001 Dec	11733018
The clinical value of 18F-FDG detection with a dual-head coincidence camera: a review.	2001 Jun	11440038
Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions.	2001 Jun	11440033
PET imaging in breast cancer.	2001 Sep	11788817
An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer.	2002 Jan	11834020
Tissue-specific differences in 2-fluoro-2-deoxyglucose metabolism beyond FDG-6-P: a 19F NMR spectroscopy study in the rat.	2003 Dec	14696007
125I-BMIPP and 18F-FDG uptake in a transgenic mouse model of stunned myocardium.	2003 Mar	12722739
F-18 FDG positron emission tomography and benign fractures.	2003 Mar	12592121
In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography.	2003 Nov	14570730
Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.	2004 Jan 15	14722036
Tissue-specific differences in 2-fluoro-2-deoxyglucose metabolism beyond FDG-6-P: a 19F NMR spectroscopy study in the rat.	2004 Jun	15229933
Extraskeletal osteosarcoma: extensive tumor thrombus on fused PET-CT images.	2005 Dec	16445001
Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells".	2006 Dec	16555088
The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression.	2006 Mar 27	16566826
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.	2007 Feb 1	17018856
Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.	2007 Mar	17454604
A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.	2007 Mar	17164229
Pulmonary echinococcosis mimicking multiple lung metastasis of breast cancer: the role of fluoro-deoxy-glucose positron emission tomography.	2008 Jan 21	18208584
Prognostic Value of FDG-PET in patients with oropharyngeal carcinoma treated with concurrent chemoradiotherapy.	2008 Jul-Aug	18528731
F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound.	2009 Aug	19617723
Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state.	2009 Feb	18534991
Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis.	2009 Mar	18925401
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.	2010 Apr 20	20406486
Hypermetabolism in patients with dementia with Lewy bodies.	2010 Jul	20548139
Importance of the gating segment in the substrate-recognition loop of pyranose 2-oxidase.	2010 Jul	20528921
Positive correlation between serum liver enzyme levels and standard uptake values of liver on FDG-PET.	2010 Mar-Apr	20189073

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:07:56 GMT 2023` Edited by `admin` on `Fri Dec 15 15:07:56 GMT 2023`
Record UNII	ZO2JV75L55
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FLUDEOXYGLUCOSE

Common Name

English

FLUDEOXYGLUCOSE [USP-RS]

Common Name

English

.ALPHA.-D-GLUCOPYRANOSE, 2-DEOXY-2-FLUORO

Common Name

English

FLUDEOXYGLUCOSE [VANDF]

Common Name

English

D-GLUCOSE, 2-DEOXY-2-FLUORO-

Systematic Name

English

Code System Code Type Description

FDA UNII

ZO2JV75L55